Liraglutide

Liraglutide is FDA-approved for two primary indications under different brand names: type 2 diabetes mellitus (as Victoza, 1.8 mg daily maximum) and chronic weight management in adults with obesity or overweight with a weight-related comorbidity (as Saxenda, 3.0 mg daily maximum). Both brands are approved for pediatric use: Victoza for children aged 10+ with T2DM, Saxenda for adolescents 12+ with obesity. LEADER also established liraglutide for cardiovascular risk reduction in T2DM patients with established CVD.

For most patients, semaglutide is more effective. STEP 8 (Rubino 2022) compared the two head-to-head for weight management and found semaglutide 2.4 mg weekly produced 15.8% weight loss vs 6.4% for liraglutide 3.0 mg daily over 68 weeks. For T2DM glycemic control, semaglutide also produces larger HbA1c reductions. However, liraglutide has advantages: longer track record (15+ years of real-world safety data), daily dosing allows faster dose adjustment if side effects emerge, and — critically — it's now available as a generic at substantially lower cost.

In SCALE (Pi-Sunyer 2015), non-diabetic adults on Saxenda 3.0 mg daily lost an average of 8.0% of body weight at 56 weeks, vs 2.6% on placebo. About 63% lost at least 5% and 33% lost at least 10%. Weight loss plateaus around 40–50 weeks and is maintained with continued treatment. The 8% ceiling is meaningfully lower than semaglutide (~15%) or tirzepatide (~21%) at maximum doses — one of the main clinical reasons liraglutide has been largely displaced for weight management by the newer drugs.

Yes — both now have generic versions on the US market. Teva launched an authorized generic of Victoza in June 2024, and Hikma received FDA approval for a typical ANDA generic in December 2024. For Saxenda, Teva launched the first generic in August 2025 at approximately 30% below branded pricing — the first weight-management-indicated GLP-1 generic in the US. Generic liraglutide is bioequivalent to the branded product. Insurance-covered pricing varies; cash prices for generic liraglutide typically run several hundred dollars per month vs ~$1,300+ for branded Saxenda.

The most common are gastrointestinal: nausea (up to 39% during titration, ~20% at maintenance), diarrhea and constipation (~20% each), vomiting (~15% during titration), and abdominal discomfort. These are largely dose-dependent and typically improve with slower titration. Rare but serious risks include pancreatitis, gallbladder disease, and a boxed warning for medullary thyroid carcinoma based on rodent data. The daily dosing produces a slightly milder GI profile than weekly GLP-1s at steady-state because peak exposures are lower.

Half-life. Liraglutide's palmitoyl (C16) fatty acid extends its half-life to ~13 hours — enough for daily dosing but not weekly. Semaglutide uses a C18 fatty diacid plus an Aib-2 substitution, which together extend the half-life to ~7 days. The difference is deliberate engineering: liraglutide (approved 2010) was the first successful attempt at an albumin-binding GLP-1, and semaglutide (2017) was Novo Nordisk's follow-up optimized for weekly dosing. Both drugs share the same basic mechanism but differ in dosing burden, peak-to-trough exposure, and weight-loss ceiling.

Indefinitely, for both indications. Like other chronic obesity and diabetes therapies, liraglutide treats relapsing-remitting disease — discontinuation leads to regression toward pre-treatment baseline. SCALE follow-up data showed that patients who discontinued Saxenda regained roughly half the lost weight within a year. For T2DM, glucose control deteriorates after discontinuation. Lifelong therapy is the expectation if the indication persists and the drug is tolerated.

Not lawfully in the US. Unlike semaglutide and tirzepatide, liraglutide was never added to the FDA Drug Shortage list in a way that permitted widespread compounding. With generic liraglutide now available at competitive prices, the economic and regulatory rationale for compounded versions has essentially disappeared. Any 'research use only' liraglutide sold by peptide vendors is not FDA-regulated and not lawful for human administration.

Yes, under prescriber guidance. Switching between GLP-1 agonists is routine. Typically the prescriber stops the current drug and starts the new one at its standard initial titration dose, rather than attempting dose-equivalent conversion — the drugs have different pharmacokinetics and side-effect profiles, so starting low on the new drug avoids compounding tolerability issues. Patients are usually advised to wait 3–7 days between stopping liraglutide (13-hour half-life) and starting the weekly alternative, though this is short relative to the week-long half-life of the incoming drug.

Yes. LEADER (Marso 2016) was the landmark cardiovascular outcomes trial — 9,340 T2DM patients with high CV risk, followed 3.5–5 years. Liraglutide reduced major adverse cardiovascular events (CV death, nonfatal MI, nonfatal stroke) by 13% vs placebo (HR 0.87, P=0.01). This was the first GLP-1 agonist to demonstrate CV benefit and established cardiovascular protection as a class effect. The FDA added cardiovascular risk reduction to Victoza's label in 2017. LEADER also showed a 22% reduction in renal endpoints in post-hoc analysis, foreshadowing the broader cardio-renal benefits now documented across the class.